|
MAP3K1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62436730732907E-12 |
| Normal-vs-Stage2 |
6.855600E-03 |
| Normal-vs-Stage3 |
2.11859974008632E-10 |
| Normal-vs-Stage4 |
2.90380000045332E-08 |
| Stage1-vs-Stage2 |
2.173500E-02 |
| Stage1-vs-Stage3 |
1.858010E-01 |
| Stage1-vs-Stage4 |
7.002000E-01 |
| Stage2-vs-Stage3 |
1.181600E-01 |
| Stage2-vs-Stage4 |
6.252400E-02 |
| Stage3-vs-Stage4 |
5.238600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
4.007100E-04 |
| Normal-vs-Asian |
4.04540000054077E-07 |
| Caucasian-vs-AfricanAmerican |
9.265400E-01 |
| Caucasian-vs-Asian |
9.889800E-01 |
| AfricanAmerican-vs-Asian |
9.278400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.82052159406021E-12 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
9.014600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
1.05582209641852E-13 |
| Normal-vs-Age(61-80Yrs) |
2.67389999997203E-06 |
| Normal-vs-Age(81-100Yrs) |
2.421700E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.251360E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.621900E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.493600E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.127020E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.844000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.659600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.429400E-01 |
| Classical-VS-Follicular |
2.88657986402541E-15 |
| Classical-VS-Other |
2.936000E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.604270E-04 |
| Tall-VS-Other |
6.134600E-01 |
| Tall-VS-Normal |
1.76132999999412E-05 |
| Follicular-VS-Other |
1.114760E-01 |
| Follicular-VS-Normal |
3.109600E-01 |
| Other-VS-Normal |
9.649700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.38500000146769E-09 |
| Normal-vs-N1 |
8.01590016585862E-10 |
| N0-vs-N1 |
2.124000E-02 |
|
|
